What research supports Turmesac®?
Turmesac® is supported by 12 preclinical studies and 6 international publications investigating inflammatory response, liver protection, antioxidant activity, bioavailability and safety.
Turmesac® / Benefits
Turmesac® Health Benefits
Turmesac® is a full-spectrum phytochemical composition derived from the rhizome of Curcuma longa. Its potential anti-inflammatory, antioxidant, hepatoprotective and cellular effects have been investigated across in-vitro and in-vivo preclinical models.
01 / Benefit
Supports a Balanced Inflammatory Response
Supports the body’s natural response to inflammatory challenges.
Turmesac® demonstrated dose-dependent activity in two acute inflammation models. At 500 mg/kg, it produced 58.65% inhibition of croton oil-induced ear edema after two hours and 57.25% inhibition after four hours. Significant reductions were also observed in a histamine-induced paw edema model.
Cell-based research provided further mechanistic support. In LPS-stimulated RAW 264.7 macrophages, 50 µg/mL Turmesac® reduced the mean fluorescence intensity of IL-8 from 50.49 in the LPS group to 19.63. IL-12 expression decreased from 68.94 to 15.79.
Mechanism
Turmesac® appears to modulate pro-inflammatory cytokines and mediators involved in vascular permeability, edema formation and inflammatory cell signalling.
Evidence
Two animal models involving 30 mice and 30 rats, divided into groups of six, plus an LPS-stimulated macrophage experiment with three replicates and 24-hour Turmesac® exposure.
02 / Benefit
Supports Liver Health and Hepatic Resilience
Helps protect liver cells against experimentally induced oxidative and chemical stress.
Turmesac® was evaluated in a paracetamol-induced liver injury model using 30 rats. Dosing at 250 and 500 mg/kg reduced elevated liver markers and improved antioxidant parameters compared with the toxic control.
At 500 mg/kg: SGOT decreased from 929 to 568 IU/L, SGPT decreased from 829 to 546 IU/L and total bilirubin decreased from 0.25 to 0.13 mg/dL. Superoxide dismutase increased from 25 to 60 units per mg protein, glutathione from 16 to 24 and catalase from 46 to 62.6.
In human-derived HepG2 liver cells exposed to hydrogen peroxide, 50 µg/mL Turmesac® reduced intracellular oxidative fluorescence from 52.5 in stressed cells to 14.43. The untreated control value was 7.72.
Mechanism
Turmesac® may support liver resilience by reducing reactive oxygen species, preserving endogenous antioxidant enzymes and limiting oxidative damage to liver cells.
Evidence
Paracetamol-induced liver injury study, N=30 rats with six animals per group, evaluated through serum biomarkers, antioxidant enzymes and liver histopathology. Supporting cell research used HepG2 and HUH-7 liver cell models.
03 / Benefit
Provides Antioxidant Protection
Supports the body’s antioxidant defence system against free-radical stress.
Turmesac® demonstrated direct free-radical scavenging activity in the DPPH antioxidant assay, with a reported IC₅₀ of 235.04 µg/mL. The reference antioxidant BHT recorded an IC₅₀ of 82.65 µg/mL in the same experiment. The study associated the antioxidant activity of Turmesac® with its turmeric-derived polysaccharide fraction.
Antioxidant effects were also observed in biological models. Turmesac® lowered hydrogen peroxide-induced reactive oxygen species in liver cells and restored glutathione, superoxide dismutase and catalase activity in the paracetamol liver injury model.
Mechanism
Turmesac® may help neutralise reactive species while supporting endogenous defence systems such as glutathione, superoxide dismutase and catalase.
Evidence
DPPH free-radical scavenging assay, hydrogen peroxide-stressed liver cell model with three replicates, and antioxidant enzyme analysis in animal liver tissue.
04 / Benefit
Investigated for Cellular Health
Preclinical studies have explored Turmesac® in abnormal cell-proliferation models.
In human cervical adenocarcinoma HeLa cells, Turmesac® produced concentration-dependent reductions in cell viability, with an IC₅₀ of 115.12 µg/mL. At this concentration, the total apoptotic cell population was reported as 83.93%, compared with 44.19% in camptothecin-treated cells. Changes were also observed in the sub-G0/G1, G0/G1 and S phases of the cell cycle.
A separate MCF-7 breast cell study reported an IC₅₀ of 163.19 µg/mL, while normal liver-derived HUH-7 cells did not show comparable cytotoxicity across the tested concentration range.
Mechanism
The laboratory findings suggest activity involving apoptosis induction, reduced cell proliferation and modulation of cell-cycle progression.
Evidence
HeLa cell MTT and flow-cytometry experiments with three replicates, supported by a separate MCF-7 cell viability study.
Important qualification: These are laboratory findings. They do not demonstrate cancer prevention, cancer therapy or anticancer efficacy in humans.
05 / Summary
Benefits at a Glance
- Supports a balanced inflammatory response
- Helps maintain liver health under oxidative stress
- Promotes the body’s antioxidant defence system
- Supports healthy cellular resilience
- Delivers a full-spectrum turmeric phytochemical matrix
- Backed by 12 preclinical studies and 6 international scientific publications
06 / Use levels
Use levels
Preclinical animal efficacy studies used 250 and 500 mg/kg body weight. Cell-based studies used concentrations ranging from 50 to 115.12 µg/mL for specific experimental endpoints.
The finished-product use level should be established using:
- The current Turmesac® product specification
- Intended product format and serving size
- Target-market regulatory requirements
- Safety and toxicology documentation
- Guidance from the Star Hi Herbs technical and regulatory teams
Acute animal safety testing evaluated doses up to 2,000 mg/kg without reported mortality or acute toxic symptoms. A 28-day study evaluated 250, 500 and 1,000 mg/kg without reported Turmesac®-related toxic effects. These findings support the preclinical safety profile but do not replace human tolerability data.
These statements have not been evaluated by the US Food and Drug Administration or the European Food Safety Authority. This product is not intended to diagnose, treat, cure or prevent any disease.
07 / FAQ
Mini FAQ
What makes Turmesac® different from isolated curcumin?
Turmesac® is a full-spectrum composition containing turmeric water-extract constituents, curcuminoids and turmeric oil, rather than a single isolated curcumin molecule.
What are the principal researched benefits?
The principal areas investigated are inflammatory response, liver protection, antioxidant defence, bioavailability and activity in experimental cellular models.
All benefit statements on this page describe preclinical in-vitro and in-vivo research. They do not establish efficacy in humans.
Request a sample or the Turmesac® scientific dossier
Full study reports, charts and histopathology images are available to qualified formulators and regulatory teams.